| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | phenazone and lidocaine (Otigo®) |
| Formulation | 40 mg/10 mg per g ear drops |
| Reference number | 4840 |
| Indication | Local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media; otitis in influenza, the so called viral bullous otitis; barotraumatic otitis |
| Company | Renascience Pharma Ltd |
| BNF chapter | Ear, nose & oropharynx |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 11/02/2021 |